On September 30, 2020,Fu Hong Han LinAn announcement was issued announcing the resignation of Dr. Scott Shi-Kau Liu as executive director and CEO of the company due to adjustments in personal work priorities. After his resignation, Dr. Liu Shigao will serve as the director of Fuhong Hanlin's Strategy Advisory Committee, and will continue to focus on the company's R&D direction, company strategy formulation, and team building and development. At the same time, the company nominated Mr. Zhang Wenjie, the current president, as the executive director of the second board of directors and appointed him as the CEO, who will lead the senior management team in the daily management of the company and supervise the operations of the company and its subsidiaries.
Mr. Zhang Wenjie
Mr. Zhang Wenjie has over 25 years of commercial operation and management experience in the pharmaceutical industry. Since joining Fuhong Hanlin in March 2019, he has been responsible for the company's operations and management, focusing on building innovative business operation models, creating an international strategic layout, and successfully promoting the smooth listing of FuhongHanlin's core product, Han Quyu®. Before joining Fuhong Hanlin, Mr. Zhang Wenjie served asAmjinGeneral Manager of China, Shanghai, ChinaRocheVice President of Oncology Business Division II, Pharmaceutical Co., Ltd., ChinaBayerHead of the Schilling Special Medicine and Oncology Department, etc.
Fosun InternationalCo-CEO,Fosun Pharmaceuticals(Market 600196) Chairman Chen Qiyu, Chairman of Fuhong Hanlin, said, “On behalf of the Board of Directors, I would like to sincerely thank Dr. Liu Shigao for his efforts and contributions to Fuhong Hanlin over the years. Under the leadership of an executive team headed by Dr. Liu Shigao, Fuhong Hanlin has sharpened a sword for ten years. It has transformed from a startup that focused relatively on R&D and clinical practice in the past to a relatively mature biomedical enterprise integrating R&D, production, and marketing. The company's board of directors and management have reached a high degree of agreement on this personnel adjustment, which is a strategic layout after careful consideration. We believe that the impact of this match on the future development of Fuhong Hanlin will be firm and positive.”
As an innovative biopharmaceutical company, Fuhong Hanlin is committed to providing high-quality and affordable innovative biopharmaceuticals to patients around the world. Its products cover the fields of tumors and autoimmune diseases. Since its establishment in 2010, thanks to the efforts of Dr. Liu Shigao and the excellent management team, the Fuhong Hanlin team has built an integrated biopharmaceutical platform. The independent core capabilities of efficiency and innovation run through the entire R&D, production and commercial operation industry chain. At the same time, a diversified, high-quality product pipeline has been forward-looking, covering more than 20 innovative monoclonal antibodies. The company successfully launched Hanlikon® (rituximab), the first biosimilar in China, and Hanquyou® (rituximab®), the first domestic biosimilar in China and Europe (trastuzumab, EU trade name: Zercepac®), and comprehensively promoted tumor immunotherapy based on its own anti-PD-1 monoclonal antibody HLX10.
Today, Fuhong Hanlin has successfully grown from an R&D team of the first two to an international biopharmaceutical company with nearly 2,000 people, with more than 100 returnees from overseas, and has continued to improve team building. In recent years, inspired by the company's mission and vision, many outstanding talents who have been responsible for drug development and production, quality technology, and commercial operations in top international biopharmaceutical companies have joined Fuhong Hanlin, including Dr. Xu Shengchang, Senior Vice President of Technology Operations, Ms. Huang Wei, Senior Vice President of Production and Engineering, Mr. Yu Cheng, Vice President of Marketing and Commercial Operations, Mr. Zeng Zuyun, Vice President of Sales, and Dr. Liu Ningshu, who recently joined the company, has a strong and experienced executive team.
Dr. Liu Shigao, co-founder of Fuhong Hanlin, said, “Unwittingly accompanying the company for more than ten years, I have witnessed Fuhong Hanlin's entrepreneurial journey from nothing, from small to big. Now that the company has established a diversified product pipeline, successfully commercialized two epoch-making products, and continues to push more high-quality innovative products into clinical trials, it has developed step by step into a leading biopharmaceutical company in China. I am very pleased and grateful. Special thanks to Fosun Pharmaceutical and Fosun International for their long-term support, and I am also very grateful to every colleague for their hard work and outstanding contributions over the years! I believe that with the support of shareholders and the leadership of the executive team headed by Wen Jie, everyone can continue to innovate, continue to excel, and reach new heights!”
Zhang Wenjie, President and CEO of Fuhong Hanlin, said, “In the future, Fuhong Hanlin will continue to adhere to the concept of 'trustworthy quality, affordable innovation', continue to explore breakthroughs in technology and innovation, lead the improvement and development of biopharmaceuticals, provide patients with high-quality and affordable innovative biopharmaceuticals, and strive to become the most trusted innovative biopharmaceutical company in the world.”